AbbVie (ABBV) Stock News and Forecasts Today: BofA Cuts Price Target to $233 as Wall Street Debates 2026 Pipeline Catalysts
AbbVie Inc. (NYSE: ABBV) stock traded higher on Monday, December 15, 2025, as investors balanced fresh analyst commentary with new exclusivity-related headlines tied to one of the company’s neuroscience brands. Shares were recently around $227, up roughly 1.7% on the session. For long-term shareholders, the bigger story remains AbbVie’s post-Humira transition: the company is leaning hard on immunology blockbusters Skyrizi and Rinvoq, while also building out oncology and neuroscience pipelines and maintaining an income-focused investor base through a growing dividend. PR Newswire+1 What’s moving AbbVie stock on Dec. 15, 2025 Two headlines stood out in Monday’s flow of AbbVie-related updates: